Ishita Drugs & Industries Ltd.
BSE: ISHITADR · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Ishita Drugs & Industries Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Ishita Drugs and Industries Limited is an Ahmedabad-based pharmaceutical company specialising in the manufacturing and export of bulk drugs, active pharmaceutical ingredients (APIs), and drug intermediates. The company operates a manufacturing facility in Sanand, Gujarat, and maintains a diverse product portfolio including vitamins, antibiotics, and anti-inflammatory agents.
Business Model
The company generates revenue through the production and sale of specialty chemicals and pharmaceutical ingredients for both domestic and international markets. It leverages its chemical synthesis capabilities to supply niche therapeutic products to clients across Southeast Asia, the Middle East, and Africa.
- Establishment Year:1992
Growth Outlook
Growth is driven by the company's focus on niche therapeutic categories such as Folic Acid and Benfotiamine. Expansion efforts are supported by its established export footprint in emerging international markets.
Key Risks
- Regulatory Compliance. The company faces risks related to maintaining international quality standards and certifications at its manufacturing facilities.
- Raw Material Price Volatility. Fluctuations in the cost of chemical precursors and raw materials can significantly impact profit margins in the bulk drug segment.
- Geopolitical Risk. Exporting to markets in the Middle East and Africa exposes the company to potential currency volatility and regional political instability.
- Market Competition. The pharmaceutical industry is highly competitive, with pricing pressures from both domestic and global manufacturers of generic APIs.
Start your research today
Unlock AI insights, financials, peers and live data on Ishita Drugs & Industries Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹15 Cr
TTM · standalone
NET PROFIT
₹0.78 Cr
TTM · standalone
EPS
₹2.60
TTM · standalone
RETURN ON EQUITY
7.1%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
10.3%
TTM · standalone
P/E
27.9x
Q4 FY26 · standalone
EV/EBITDA
16.7x
Q4 FY26 · standalone
EBITDA MARGIN
8.5%
TTM · standalone
NET PROFIT MARGIN
5.9%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Ishita Drugs & Industries Ltd.ISHITADR | ₹22 Cr | 28.46 | 17.65 | -2.1% | 8.5% | 7.1% | 10.3% | -1.5% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Q4 FY26
Financials
Ishita Drugs & Industries Ltd.
BSE: ISHITADR · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Ishita Drugs & Industries Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Ishita Drugs and Industries Limited is an Ahmedabad-based pharmaceutical company specialising in the manufacturing and export of bulk drugs, active pharmaceutical ingredients (APIs), and drug intermediates. The company operates a manufacturing facility in Sanand, Gujarat, and maintains a diverse product portfolio including vitamins, antibiotics, and anti-inflammatory agents.
Business Model
The company generates revenue through the production and sale of specialty chemicals and pharmaceutical ingredients for both domestic and international markets. It leverages its chemical synthesis capabilities to supply niche therapeutic products to clients across Southeast Asia, the Middle East, and Africa.
- Establishment Year:1992
Growth Outlook
Growth is driven by the company's focus on niche therapeutic categories such as Folic Acid and Benfotiamine. Expansion efforts are supported by its established export footprint in emerging international markets.
Key Risks
- Regulatory Compliance. The company faces risks related to maintaining international quality standards and certifications at its manufacturing facilities.
- Raw Material Price Volatility. Fluctuations in the cost of chemical precursors and raw materials can significantly impact profit margins in the bulk drug segment.
- Geopolitical Risk. Exporting to markets in the Middle East and Africa exposes the company to potential currency volatility and regional political instability.
- Market Competition. The pharmaceutical industry is highly competitive, with pricing pressures from both domestic and global manufacturers of generic APIs.
Start your research today
Unlock AI insights, financials, peers and live data on Ishita Drugs & Industries Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹15 Cr
TTM · standalone
NET PROFIT
₹0.78 Cr
TTM · standalone
EPS
₹2.60
TTM · standalone
RETURN ON EQUITY
7.1%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
10.3%
TTM · standalone
P/E
27.9x
Q4 FY26 · standalone
EV/EBITDA
16.7x
Q4 FY26 · standalone
EBITDA MARGIN
8.5%
TTM · standalone
NET PROFIT MARGIN
5.9%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q4 FY26